v3.25.3
Strategic Agreements - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Derivative liabilities - royalty agreement   $ 1,922   $ 1,922   $ 1,647
Ligand Development Funding Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payments totalling to fund development $ 15,000          
Maximum payments to receive upon achievement of milestones $ 8,000          
Agreement royalty term period from first sale 15 years          
Agreement termination notice period 90 days          
Aggregate potential future milestone payments remaining under arrangement   5,000   5,000    
Derivative liabilities - royalty agreement   1,900   1,900   1,600
Long-term liability   16,000   $ 16,000   $ 11,900
Effective interest rate percentage of potential future royalty payments       39.90%   39.90%
Non-cash interest expense   $ 1,500 $ 1,000 $ 4,100 $ 2,800  
Ligand Development Funding Agreement [Member] | Maximum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalty percentage 9.80%          
Ligand Development Funding Agreement [Member] | Minimum            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalty percentage 8.00%